Key result
Amlodipine fails to activate CRAC channels at therapeutic doses, debunking prior autofluorescence artifacts.
Why the study?
Concerns existed that L-type calcium channel blockers could activate CRAC channels and increase the risk of heart failure.
Does amlodipine activate CRAC channels at therapeutic concentrations in cellular models?
Does amlodipine activate CRAC channels at therapeutic concentrations in cellular models?
Answers are grounded in this paper and cite their sources.
Amlodipine does not activate CRAC channels at therapeutic concentrations, reassuring its safety profile as a front-line anti-hypertensive therapy without increasing heart failure risk via this mechanism.
Amlodipine has been used as a front-line anti-hypertensive therapy for decades by virtue of blocking voltage-operated calcium channels with high affinity and specificity. Recently, the safety of amlodipine has been questioned, as it was reported to activate Ca2+ release-activated Ca2+ (CRAC) channels and increase the risk of heart failure. Here we show, using a variety of approaches, that amlodipine does not activate CRAC channels at therapeutic concentrations. Combined with our previous meta-analysis, our study should reassure physicians that amlodipine should continue to be prescribed for treating hypertension.
No takes yet. Share an insight, caveat, or question.
Bird et al. (2025) studied Hypertension. Amlodipine vs. Vehicle was evaluated on CRAC channel activation (cytosolic Ca2+ signals). Amlodipine does not activate CRAC channels at therapeutic concentrations, indicating that previous reports of activation were artifacts caused by intracellular amlodipine autofluorescence.
Synapse has enriched 10 related papers. Consider them for comparative context: